-
-
Optimal treatment for carcinoma of unknown primary has not been established. In a multicenter, randomized Phase II trial, 66 patients were treated with cisplatin, gemcitabine and either paclitaxel or vinorelbine.
-
In 47 patients with newly diagnosed colorectal cancer, staging by combined CT and PET was compared to CT followed at a later time by PET or by CT alone.
-
-
-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
Delays in starting radiation therapy for high-risk localized prostate cancer were shown in this retrospective review to be associated with a greater risk for disease relapse, as witnessed by PSA recurrence. For patients with low-risk disease, however, comparable delays were not associated with greater risk for relapse.
-
Survivors 2 years or more after autologous stem cell transplant for AML, ALL, NHL, and HD remain at significant risk of death, with 29% mortality, almost entirely between 2 and 10 years after transplant. While 56% died of relapse of the primary disease, 43% died from treatment related complications, many of whom suffered from therapy related MDS or AML.
-
The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA/LV/5-FU.
-
Factors associated with leukemia development in patients with polycythemia vera were examined in a cohort of 1638 patients enrolled in an observational study. Older age, alkylating agent treatment and female gender were demonstrated to be significant risks, hydroxyurea treatment was not.